Drugs / Optive
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 44 trials | ||||||
| Phase 4 | NCT00469573 | May 2007 → Mar 2008 | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00469157 | May 2007 → Apr 2008 | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00399230 | — | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00406510 | — | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02806830 | Apr 2016 → Jan 2017 | degenerative myopia, diabetic retinopathy, macular degeneration, retinal artery occlusion | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 3 | NCT02871440 Comparator | Sep 2016 → Sep 2017 | dry eye syndrome | The University of New South Wales | Completed | No outcome recorded |
| Phase 4 | NCT00698945 Comparator | Jun → Nov 2008 | ocular hypertension, open-angle glaucoma | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00698724 Comparator | Jun 2008 → Jun 2009 | cataract | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00570843 Comparator | Mar 2008 → Feb 2010 | — | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00399061 Comparator | Nov 2006 → Sep 2008 | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| — | NCT00610480 Comparator | Nov 2007 → Mar 2009 | dry eye syndrome | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Optive | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00610480 ↗ |
| Known as | NGT | “To evaluate the effectiveness of NGT (Optive) vs. Systane Tears for patients with moderate to severe dry eye disease.” NCT00399230 ↗ |
| Modality | Other / unclassified | “Artificial Tears (Optive, 40 microliters) will be administered at the first study visit” NCT00610480 ↗ |
| Route | Other | “Optive 15ml (in the eye)” NCT00399061 ↗ |